Tear Interleukin Biomarkers After Glaucoma Treatment
Recruiting
N/A
Interventional Study
Glaucoma
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 24 (estimated)
- Sponsor
- Kazakh Eye Research Institute · Research network
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This prospective study aims to evaluate inflammatory biomarkers in tear fluid in patients with glaucoma undergoing micropulse transscleral cyclophotocoagulation (MP-CPC), continuous-wave cyclophotocoagulation (CPC), and antiglaucoma surgeries. The study will assess the concentrations of pro- and anti-inflammatory interleukins in tear samples collected before treatment, 5-7 days after the procedure…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Decision to treat by MP-CPC Laser
* Patients diagnosed with Glaucoma
* Patients aged 18 years old and above
* Glaucoma that is inadequately controlled on medical therapy
Exclusion Criteria:
* Patients age less than 18 years
* Patients unable or unwilling to provide informed …
Contacts